At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LIMN Liminatus Pharma LLC
Not Yet Opened 06-25 16:00:00 EDT
0.0990
-0.0041
-3.98%
盘后0.0999
+0.0009+0.91%
19:51 EDT
High0.1061Low0.0950Vol914.66K
Open0.1061D1 Closing0.1031Amplitude10.77%
Mkt Cap4.44MTradable Cap945.96KTotal Shares44.88M
T/O91.55KT/O Rate9.57%Tradable Shares9.56M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Liminatus Pharma issues new warrants for 20,688,000 shares in inducement deal
Reuters  ·  06-03
Liminatus Pharma issues new warrants for 20,688,000 shares in inducement deal
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
THOMSON REUTERS  ·  06-03
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
Liminatus Pharma appeals Nasdaq delisting notice after missing $50 million market value rule
Reuters  ·  05-28
Liminatus Pharma appeals Nasdaq delisting notice after missing $50 million market value rule
Liminatus Pharma receives Nasdaq delisting notice
TIPRANKS  ·  05-22
Liminatus Pharma receives Nasdaq delisting notice
Liminatus Pharma appeals Nasdaq delisting notice, trading suspension set May 29
Reuters  ·  05-22
Liminatus Pharma appeals Nasdaq delisting notice, trading suspension set May 29
Liminatus Pharma Announces Nasdaq Delisting Notification
THOMSON REUTERS  ·  05-22
Liminatus Pharma Announces Nasdaq Delisting Notification
NASD Most Active Issues
Dow Jones  ·  05-22
NASD Most Active Issues
Liminatus Pharma agrees to merge with InnocsAI in $320 million stock deal
Reuters  ·  05-21
Liminatus Pharma agrees to merge with InnocsAI in $320 million stock deal
Liminatus Pharma Inc - Innocsai Members to Receive 20% of Future Net Proceeds From Certain Strategic Deals
THOMSON REUTERS  ·  05-21
Liminatus Pharma Inc - Innocsai Members to Receive 20% of Future Net Proceeds From Certain Strategic Deals
Liminatus Pharma Announces Proposed Merger With Innocsai to Expand Oncology Cell Therapy Pipeline
THOMSON REUTERS  ·  05-21
Liminatus Pharma Announces Proposed Merger With Innocsai to Expand Oncology Cell Therapy Pipeline
Top Premarket Gainers
MT Newswires Live  ·  05-21
Top Premarket Gainers
Liminatus Pharma Inc - Enters Merger Agreement With Innocsai Llc on May 17, 2026 - SEC Filing
THOMSON REUTERS  ·  05-21
Liminatus Pharma Inc - Enters Merger Agreement With Innocsai Llc on May 17, 2026 - SEC Filing
Liminatus Pharma Inc - Innocsai Members to Receive 1.6 Bln Shares at $0.20 per Share and 20% Contingent Value Rights - SEC Filing
THOMSON REUTERS  ·  05-21
Liminatus Pharma Inc - Innocsai Members to Receive 1.6 Bln Shares at $0.20 per Share and 20% Contingent Value Rights - SEC Filing
Liminatus Pharma agrees to buy InnocsAI in 1,600,000,000-share deal at $0.2 each
Reuters  ·  05-21
Liminatus Pharma agrees to buy InnocsAI in 1,600,000,000-share deal at $0.2 each
Liminatus Pharma Q1 FY26 net loss widens to $1.12 million; operating loss widens 317% to $1.1 million
Reuters  ·  05-16
Liminatus Pharma Q1 FY26 net loss widens to $1.12 million; operating loss widens 317% to $1.1 million
NASD Most Active Issues
Dow Jones  ·  04-16
NASD Most Active Issues
Liminatus Pharma FY25 net loss widens to $10.2 million; operating loss narrows to $3 million
Reuters  ·  04-01
Liminatus Pharma FY25 net loss widens to $10.2 million; operating loss narrows to $3 million
Liminatus Pharma plans Phase 1 trial of CD47 antibody IBA101 in lung cancer
Reuters  ·  03-17
Liminatus Pharma plans Phase 1 trial of CD47 antibody IBA101 in lung cancer
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of Iba101, a Next-Generation Cd47 Blocking Antibody
THOMSON REUTERS  ·  03-17
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of Iba101, a Next-Generation Cd47 Blocking Antibody
Liminatus Pharma Cuts Shareholder Meeting Quorum to One-Third
Reuters  ·  03-05
Liminatus Pharma Cuts Shareholder Meeting Quorum to One-Third

Introduction

Company Name.
Liminatus Pharma LLC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Iris Acquisition Corp does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was formerly known as Tribe Capital Growth Corp I and changed its name to Iris Acquisition Corp in July 2022. The company was incorporated in 2020 and is based in George Town, Cayman Islands. Iris Acquisition Corp is a subsidiary of Iris Acquisition Holdings LLC.
Issue price:
--